Results from the Phase II COLLECTiVE202 trial (NCT05370885) demonstrated a statistically significant difference between VE202 ...

In this Q&A, Rohit Nambisan, CEO of Lokavant, and Jonathan Crowther, head of predictive analytics, Pfizer, explore how AI is ...

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.

Schrödinger has halted development of its cancer-fighting candidate SGR-2921 after two patients treated with the CDC7 inhibitor died in a Phase I trial.

August 14, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL ® siRNA gene silencing technology to ...

Key Points GAAP loss per share of $(0.47) for Q2 2025 was narrower than the $(0.53) analysts had expected, despite an ongoing absence of revenue. Research and development expenses (GAAP) increased 35.

Identifying specific biomarkers and clinical characteristics is crucial for predicting a patient's response to both existing and emerging treatments for chronic spontaneous urticaria, thereby moving ...

Net loss (GAAP) narrowed to $6.1 million in Q2 2025, a 22.8% improvement from the prior-year period, driven by reduced research and development spending. No product revenue reported; The company’s ...

HHS' decision "could stagnate research that has the potential to save millions of lives," writes Simon Williams.

Q2 2025 Earnings Call Transcript August 14, 2025 Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is $-3 ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...

GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2's formal safety review, it has advanced into Cohort 3 and ...